Loading...
XWAR
CRM
Market cap10mUSD
Jul 09, Last price  
0.49PLN
1D
-2.00%
1Q
-17.79%
Jan 2017
-76.44%
IPO
-87.90%
Name

PZ Cormay SA

Chart & Performance

D1W1MN
XWAR:CRM chart
P/E
P/S
0.43
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
8.08%
Revenues
96m
+5.11%
31,085,00038,451,00061,940,00090,027,000105,473,000100,800,000100,111,00045,004,00082,277,00077,585,00069,793,00068,410,00065,290,00084,732,00085,361,00082,225,00091,623,00096,305,000
Net income
-4m
L-20.98%
1,420,0002,956,0006,130,00014,008,00015,382,0006,853,000-47,357,000-5,157,000-10,990,000-2,021,000-24,982,000-40,974,000-12,665,0001,635,000-6,963,000-4,534,000-5,267,000-4,162,000
CFO
-699k
L-73.41%
2,203,000-1,582,000-9,747,0002,334,0002,254,000-17,451,0007,928,000-5,271,000-5,167,0001,656,000-1,561,000-4,390,000-161,000-1,469,000-8,709,000-3,249,000-2,629,000-699,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PZ Cormay S.A., a diagnostic company, provides IVD solutions in Poland and internationally. The company offers analyzers, reagents, cleaning liquids, calibrators, control materials, patterns, and agglutination tests. It also provides analyzers, test strips, inspections, and calibration strips. In addition, the company offers parasitology, such as Paragreen Mini-System, a specialized device for concentrating and preserving stool samples, as well as veterinary medicines. Further, it provides immunochemistry, including SNIBE, MINDRAY, DIESSE, and AliveDX, as well as molecular biology, such as RT-PCR systems, systems for isolating genetic material, workstations, RT-PCR reagent kits, and nucleic acid isolation reagent kits. Additionally, the company offers sampling comprising blood and urine samples and supporting materials, as well as Sentimag systems, Magtrace markers, Magseed Markers, and surgical instruments, as well as HPLC systems, point of care diagnostics, and integrated systems. The company was founded in 1985 and is based in Lomianki, Poland.
IPO date
Aug 20, 2008
Employees
222
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT